These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26353895)

  • 1. Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.
    Ouwerkerk-Mahadevan S; Snoeys J; Peeters M; Beumont-Mauviel M; Simion A
    Clin Pharmacokinet; 2016 Feb; 55(2):197-208. PubMed ID: 26353895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach.
    Snoeys J; Beumont M; Monshouwer M; Ouwerkerk-Mahadevan S
    Clin Pharmacol Ther; 2016 Feb; 99(2):224-34. PubMed ID: 26259716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
    Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
    Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Drug-Drug Interaction Profile of Presatovir.
    Xin Y; Weng W; Murray BP; Eisenberg EJ; Chien JW; Ling J; Silverman JA
    J Clin Pharmacol; 2018 Jun; 58(6):771-780. PubMed ID: 29412463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
    Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
    AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telaprevir: pharmacokinetics and drug interactions.
    Garg V; Kauffman RS; Beaumont M; van Heeswijk RP
    Antivir Ther; 2012; 17(7):1211-21. PubMed ID: 22954756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
    Eley T; Garimella T; Li W; Bertz RJ
    Clin Pharmacokinet; 2015 Dec; 54(12):1205-22. PubMed ID: 26177803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical drug interaction profile of idelalisib in healthy subjects.
    Jin F; Robeson M; Zhou H; Moyer C; Wilbert S; Murray B; Ramanathan S
    J Clin Pharmacol; 2015 Aug; 55(8):909-19. PubMed ID: 25760671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions.
    Yoshikado T; Maeda K; Furihata S; Terashima H; Nakayama T; Ishigame K; Tsunemoto K; Kusuhara H; Furihata KI; Sugiyama Y
    Pharm Res; 2017 Aug; 34(8):1570-1583. PubMed ID: 28484975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.
    Dixit V; Hariparsad N; Li F; Desai P; Thummel KE; Unadkat JD
    Drug Metab Dispos; 2007 Oct; 35(10):1853-9. PubMed ID: 17639026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease.
    Monteagudo E; Fonsi M; Chu X; Bleasby K; Evers R; Pucci V; Orsale MV; Cianetti S; Ferrara M; Harper S; Laufer R; Rowley M; Summa V
    Xenobiotica; 2010 Dec; 40(12):826-39. PubMed ID: 20925584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.
    Yu J; Zhou Z; Tay-Sontheimer J; Levy RH; Ragueneau-Majlessi I
    Drug Metab Dispos; 2018 Jun; 46(6):835-845. PubMed ID: 29572333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
    Tsantrizos YS
    Curr Opin Investig Drugs; 2009 Aug; 10(8):871-81. PubMed ID: 19649931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein.
    Robertson SM; Luo X; Dubey N; Li C; Chavan AB; Gilmartin GS; Higgins M; Mahnke L
    J Clin Pharmacol; 2015 Jan; 55(1):56-62. PubMed ID: 25103957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach.
    Valade E; Valenzuela B; Kakuda TN; Westland C; McClure MW; Ouwerkerk-Mahadevan S; Perez-Ruixo JJ; Ackaert O
    AAPS J; 2018 Oct; 20(6):111. PubMed ID: 30350297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.
    Marra F; Höner Zu Siederdissen C; Khoo S; Back D; Schlag M; Ouwerkerk-Mahadevan S; Bicer C; Lonjon-Domanec I; Jessner W; Beumont-Mauviel M; Kalmeijer R; Cornberg M
    Br J Clin Pharmacol; 2018 May; 84(5):961-971. PubMed ID: 29345798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone drug-drug interaction studies: a comprehensive review.
    Chiu YY; Ereshefsky L; Preskorn SH; Poola N; Loebel A
    Drug Metabol Drug Interact; 2014; 29(3):191-202. PubMed ID: 24825095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.